Schimmel Paul's Form 4 filing
aTYR PHARMA INC (ATYR) · filed Sep 22, 2021
- Accession no.
- 0001209191-21-057339
- Filed
- Sep 22, 2021
- Trade date
- Sep 20, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $2.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schimmel PaulCIK 0001236447 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 20, 2021 | Common Stock | PPurchaseAcquired | +250,000 | $8.00F1 | +$2,000,000 | 252,890 | Direct | |
| Sep 20, 2021 | Common Stock | GGiftDisposed | −250,000 | $0.00 | $0 | 2,890 | Direct | |
| Sep 20, 2021 | Common Stock | GGiftAcquired | +250,000 | $0.00 | $0 | 679,143 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents shares purchased in an underwritten public offering at a public offering price of $8.00 per share.
Referenced by the price of 1 transaction in Table I.